Charles River Laboratories International Bilan de santé
Santé financière contrôle des critères 4/6
Charles River Laboratories International possède un total de capitaux propres de $3.8B et une dette totale de $2.3B, ce qui porte son ratio d'endettement à 60.1%. Son actif total et son passif total sont $8.0B et de $4.2B. L'EBIT de Charles River Laboratories International est $608.6M ce qui fait que son ratio de couverture des intérêts 4.9. Elle dispose de liquidités et de placements à court terme de $210.2M.
Informations clés
60.1%
Ratio d'endettement
US$2.30b
Dette
| Ratio de couverture des intérêts | 4.9x |
| Argent liquide | US$210.17m |
| Fonds propres | US$3.83b |
| Total du passif | US$4.18b |
| Total des actifs | US$8.00b |
Mises à jour récentes de la santé financière
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03Recent updates
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19Analyse de la situation financière
Passif à court terme: Les actifs à court terme de CRL ( $1.5B ) dépassent ses passifs à court terme ( $1.0B ).
Passif à long terme: Les actifs à court terme de CRL ( $1.5B ) ne couvrent pas ses passifs à long terme ( $3.2B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de CRL ( 54.6% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de CRL a été réduit de 120.6% à 60.1% au cours des 5 dernières années.
Couverture de la dette: La dette de CRL est bien couverte par le flux de trésorerie opérationnel ( 34.6% ).
Couverture des intérêts: Les paiements d'intérêts de CRL sur sa dette sont bien couverts par l'EBIT ( 4.9 x couverture).